Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has committed up to $3 billion in a deal with Lanova Medicines focused on PD-1/VEGF. The deal comes as Merck faces competition from Bristol Myers Squibb in leukemia, leading Allogene to end phase I enrollment. Analysts view Merck's move as conservative, despite recent excitement around PD-1/VEGF. In other news, GSK is making a case for Blenrep in multiple myeloma, while Adaptimmune plans to submit a rolling BLA for its sarcoma cell therapy. PTC has received the first FDA approval for direct-to-brain gene therapy. Additionally, Marinus Pharmaceuticals has laid off 45% of its employees. Transitioning to other topics, we also cover Biogen's stock performance, a significant deal in the CDMO sector, and recent developments in the pharmaceutical industry.